CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...

Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Radich is a ...

With results from a head-to-head study comparing its newer chronic myeloid leukemia (CML) treatment Scemblix to its own standard-of-care tyrosine kinase inhibitor (TKI) Gleevec in newly diagnosed ...

A novel panel to detect microsatellite instability and concordance with clinical reference methods in colorectal cancer patients. Neutrophil/lymphocyte ratio (NLR) and FDG PET as predictive measures ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

Kendra L. Sweet, MD, a SWOG investigator at Moffitt Cancer Center, reports results of the SWOG S1712 clinical trial at the ESH-iCMLf John Goldman Conference on CML in Prague, September 27th. The phase ...

SAN DIEGO — Some patients with chronic myeloid leukemia (CML) may be able to safely cut the dose of tyrosine kinase inhibitors (TKIs) in half and lower the rate of adverse effects without risking a ...

NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel may be superior to the already highly effective standard medicine Gleevec in treating newly diagnosed patients with chronic ...